

[CLAIMS]

[Claim 1]

Use of an antibody that binds to latent myostatin in the manufacture of a pharmaceutical formulation for treating a muscle wasting disease, wherein the antibody comprises:

- (a) a VH sequence of SEQ ID NO: 86 and a VL sequence of SEQ ID NO: 96;
- (b) a VH sequence of SEQ ID NO: 87 and a VL sequence of SEQ ID NO: 96;
- (c) a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO: 96;
- (d) a VH sequence of SEQ ID NO: 89 and a VL sequence of SEQ ID NO: 96;
- (e) a VH sequence of SEQ ID NO: 90 and a VL sequence of SEQ ID NO: 96;
- (f) a VH sequence of SEQ ID NO: 91 and a VL sequence of SEQ ID NO: 96;
- (g) a VH sequence of SEQ ID NO: 92 and a VL sequence of SEQ ID NO: 97;
- (h) a VH sequence of SEQ ID NO: 93 and a VL sequence of SEQ ID NO: 97;
- (i) a VH sequence of SEQ ID NO: 94 and a VL sequence of SEQ ID NO: 97; or
- (j) a VH sequence of SEQ ID NO: 95 and a VL sequence of SEQ ID NO: 97.

[Claim 2]

Use of an antibody that binds to latent myostatin in the manufacture of a pharmaceutical formulation for increasing mass of muscle tissue, wherein the antibody comprises;

- (a) a VH sequence of SEQ ID NO: 86 and a VL sequence of SEQ ID NO: 96;
- (b) a VH sequence of SEQ ID NO: 87 and a VL sequence of SEQ ID NO: 96;
- (c) a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO: 96;
- (d) a VH sequence of SEQ ID NO: 89 and a VL sequence of SEQ ID NO: 96;
- (e) a VH sequence of SEQ ID NO: 90 and a VL sequence of SEQ ID NO: 96;
- (f) a VH sequence of SEQ ID NO: 91 and a VL sequence of SEQ ID NO: 96;
- (g) a VH sequence of SEQ ID NO: 92 and a VL sequence of SEQ ID NO: 97;
- (h) a VH sequence of SEQ ID NO: 93 and a VL sequence of SEQ ID NO: 97;
- (i) a VH sequence of SEQ ID NO: 94 and a VL sequence of SEQ ID NO: 97; or
- (j) a VH sequence of SEQ ID NO: 95 and a VL sequence of SEQ ID NO: 97.

[Claim 3]

Use of an antibody that binds to latent myostatin in the manufacture of a pharmaceutical formulation for increasing strength of muscle tissue, wherein the antibody comprises:

- (a) a VH sequence of SEQ ID NO: 86 and a VL sequence of SEQ ID NO: 96;
- (b) a VH sequence of SEQ ID NO: 87 and a VL sequence of SEQ ID NO: 96;
- (c) a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO: 96;
- (d) a VH sequence of SEQ ID NO: 89 and a VL sequence of SEQ ID NO: 96;
- (e) a VH sequence of SEQ ID NO: 90 and a VL sequence of SEQ ID NO: 96;
- (f) a VH sequence of SEQ ID NO: 91 and a VL sequence of SEQ ID NO: 96;
- (g) a VH sequence of SEQ ID NO: 92 and a VL sequence of SEQ ID NO: 97;
- (h) a VH sequence of SEQ ID NO: 93 and a VL sequence of SEQ ID NO: 97;
- (i) a VH sequence of SEQ ID NO: 94 and a VL sequence of SEQ ID NO: 97; or
- (j) a VH sequence of SEQ ID NO: 95 and a VL sequence of SEQ ID NO: 97.

[Claim 4]

Use of an antibody that binds to latent myostatin in the manufacture of a pharmaceutical formulation for reducing body fat accumulation, wherein the antibody comprises:

- (a) a VH sequence of SEQ ID NO: 86 and a VL sequence of SEQ ID NO: 96;
- (b) a VH sequence of SEQ ID NO: 87 and a VL sequence of SEQ ID NO: 96;
- (c) a VH sequence of SEQ ID NO: 88 and a VL sequence of SEQ ID NO: 96;
- (d) a VH sequence of SEQ ID NO: 89 and a VL sequence of SEQ ID NO: 96;
- (e) a VH sequence of SEQ ID NO: 90 and a VL sequence of SEQ ID NO: 96;
- (f) a VH sequence of SEQ ID NO: 91 and a VL sequence of SEQ ID NO: 96;
- (g) a VH sequence of SEQ ID NO: 92 and a VL sequence of SEQ ID NO: 97;
- (h) a VH sequence of SEQ ID NO: 93 and a VL sequence of SEQ ID NO: 97;
- (i) a VH sequence of SEQ ID NO: 94 and a VL sequence of SEQ ID NO: 97; or
- (j) a VH sequence of SEQ ID NO: 95 and a VL sequence of SEQ ID NO: 97.

[Claim 5]

The use according to any one of claims 1 to 4, wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 352, and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 10.

[Claim 6]

The use according to any one of claims 1 to 5, wherein the antibody is a full length IgG antibody.